Effectiveness and safety of enfortumab vedotin and pembrolizumab in a real-world patient population with urothelial carcinoma: results from a multi-institutional cohort (GUARDIANS)
Enfortumab vedotin plus pembrolizumab (EVP) is the standard first-line treatment for metastatic or locally advanced urothelial carcinoma (m/laUC). Real-world patients frequently present with unfavorable clinical characteristics, raising uncertainty about whether outcomes mirror those of the pivotal...
Salvato in:
| Autori principali: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Natura: | Article (Journal) |
| Lingua: | inglese |
| Pubblicazione: |
12 July 2026
|
| In: |
Cancer immunology immunotherapy
Year: 2026, Volume: 75, Fascicolo: 7, Pages: 1-14 |
| ISSN: | 1432-0851 |
| DOI: | 10.1007/s00262-026-04448-2 |
| Accesso online: | Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s00262-026-04448-2 Verlag, kostenfrei, Volltext: https://link.springer.com/article/10.1007/s00262-026-04448-2 |
| Note sull'autore: | Stefanie Zschäbitz, Irfan Bhatti, Jozefina Casuscelli, Ludwig Otto Pachmayr, Thomas Büttner, Thomas Elegeert, Nina Holzwarth, Severin Rodler, Martin Hennig, Emily Rinderknecht, Muammar Dib, Katrin Schlack, Christopher Darr, Anna-Lisa Volk, Philipp Schmucker, Friedemann Zengerling, Pia Paffenholz, Joschka Heil, Eva Erne, Subhajit Mandal, Frederik Wessels, Thea Maria Busse, Daniel Seidl, Susan Foller, Alexander Höllein, Tim Nestler, Christian Gratzke, Louis Rhode, Jakob Kohler, Günter Niegisch, Anna Katharina Seitz, Julia Heinzelbecker, Niklas Klümper, Margitta Retz, Viktor Grünwald, Can Aydogdu, Marco Julius Schnabel |
| Riassunto: | Enfortumab vedotin plus pembrolizumab (EVP) is the standard first-line treatment for metastatic or locally advanced urothelial carcinoma (m/laUC). Real-world patients frequently present with unfavorable clinical characteristics, raising uncertainty about whether outcomes mirror those of the pivotal EV-302/KEYNOTE-A39 trial. This study assessed effectiveness and safety of EVP in a real-world cohort of patients with m/laUC. |
|---|---|
| Descrizione del documento: | Online veröffentlicht: 12. Juli 2026, Artikelversion: 13. Juli 2026 Gesehen am 03.08.2026 |
| Descrizione fisica: | Online Resource |
| ISSN: | 1432-0851 |
| DOI: | 10.1007/s00262-026-04448-2 |